Correction: *What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. A meta-analysis and functional study*

Sepriano A, Ramiro S, van der Heijde D, *et al.* What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. A meta-analysis and functional study. *Ann Rheum Dis* 2020;79:324–31.

The values for some of the features in the SPACE cohort were switched between patients included and excluded in the analysis. The appropriate corrections were made in [table 1](#) and online supplementary table S1. The text in the results section was also corrected: “In SPACE, included patients were less likely to be HLA-B27 positive (37% *vs* 57%) (...).”

Table 1 Baseline patient characteristics in the space and DESIR cohorts

	Space (n=465)	Desir (n=576)
Age at baseline (years)	31 (8)	33 (8)
Male gender	161 (35)	269 (47)
Symptom duration (years)	1.8 (2.3)	1.5 (0.8)
ASAS axSpA criteria	172 (37)	358 (62)
axSpA according to Rheumatologist*	136 (30)	269 (47)
ASAS pSpA criteria	182 (39)	320 (56)
ASAS SpA criteria†	249 (54)	443 (77)
Sacroiliitis on MRI-SIJ (ASAS)	64 (14)	153 (27)
BME on MRI-spine (≥5 lesions)	21 (5)	25 (4)
Radiographic sacroiliitis (mNY)	38 (8)	78 (14)
≥1 syndesmophyte on X-spine	15 (3)	39 (7)
Elevated CRP (≥6 mg/L)	118 (25)	169 (29)
Good response to NSAIDs ever	189 (41)	491 (85)
Peripheral arthritis ever	76 (16)	122 (21)
Dactylitis ever	23 (5)	78 (14)
Heel enthesitis ever	91 (20)	261 (45)

Supplementary Table Patient characteristics comparing those included in LCA to those not (SPACE cohort)

	All (n=748)	Included in LCA (n=465)	NOT included in LCA (n=283)	P value
Age at baseline (years)	31 (8)	31 (8)	30 (8)	0.35
Male gender	287 (39)	161 (35)	126 (45)	0.01
Symptom duration (years)	2 (2)	2 (2)	2 (2)	0.93
Inflammatory back pain	513 (69)	308 (66)	205 (74)	0.027
ASAS axSpA criteria	308 (42)	172 (37)	133 (52)	<0.01
ASAS pSpA criteria	281 (39)	182 (39)	99 (39)	0.93
ASAS SpA criteria†	412 (57)	249 (54)	163 (64)	0.01
axSpA according to Rheumatologist*	255 (35)	136 (30)	119 (45)	<0.01
HLA-B27	328 (44)	172 (37)	156 (57)	<0.01
Dactylitis ever	41 (6)	23 (5)	18 (6)	0.39
Uveitis ever	60 (8)	33 (7)	27 (10)	0.21
Family history of SpA	317 (43)	194 (42)	123 (44)	0.50
Inflammatory bowel disease ever	51 (7)	35 (8)	16 (6)	0.34
Psoriasis ever	95 (13)	54 (12)	41 (15)	0.23
Peripheral arthritis ever	117 (16)	76 (16)	41 (15)	0.56
Heel enthesitis ever	146 (20)	91 (20)	55 (20)	0.96
Current arthritis / any enthesitis / dactylitis	475 (64)	317 (68)	158 (58)	<0.01
Elevated CRP (≥6 mg/L)	182 (25)	118 (25)	64 (24)	0.57
Good response to NSAIDs ever	327 (45)	189 (41)	138 (53)	<0.01
Number of SpA features (0–9)‡	2 (1)	2 (1)	2 (1)	0.35
Radiographic sacroiliitis (mNY)	55 (9)	38 (8)	17 (11)	0.26
Sacroiliitis on MRI-SIJ (ASAS)	106 (18)	64 (14)	42 (30)	<0.01
BME on MRI-spine (≥5 lesions)	25 (4)	21 (5)	4 (3)	0.42
≥1 syndesmophyte on X-spine	20 (4)	15 (3)	5 (9)	0.06

	Space (n=465)	Desir (n=576)
HLA-B27	172 (37)	345 (60)
Family history of SpA	194 (42)	250 (43)
Psoriasis ever	54 (12)	99 (17)
Uveitis ever	33 (7)	52 (9)
Inflammatory Bowel Disease ever	35 (8)	25 (4)
Current arthritis / any enthesitis / dactylitis	317 (68)	398 (69)
Inflammatory back pain	308 (66)	576 (100)
Number of SpA features (0–9)‡	2 (1)	3 (1)

Values are mean (SD) for continuous variables or number (%) for binary variables. SpA features are positive if 'ever present' (any time in the past and/or baseline).

*Clinical diagnosis of axSpA at baseline with a level of confidence >7; Missing data SPACE: axSpA according to Rheumatologist (n=454); Symptom duration (n=461); missing data DESIR: axSpA according to Rheumatologist (n=576).

†fulfilment of either ASAS axSpA or ASAS pSpA classification criteria.

‡peripheral arthritis, heel enthesitis, dactylitis, psoriasis, uveitis, inflammatory bowel disease, good response to NSAIDs, elevated CRP and family history of SpA.

ASAS, Assessment of SpondyloArthritis international Society; axSpA, axial spondyloarthritis; BME, bone marrow oedema; CRP, C-reactive protein; mNY, modified New York criteria; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-inflammatory drugs; pSpA, peripheral spondyloarthritis; SD, standard deviation; SIJ, sacroiliac joints; X-spine, radiograph of the spine.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2020;**79**:e78. doi:10.1136/annrheumdis-2019-216516corr1